Repligen (RGEN) has received a new Buy rating, initiated by TD Cowen analyst, Brendan Smith.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Brendan Smith has given his Buy rating due to a combination of factors that highlight Repligen’s strong market position and growth potential. The company’s performance in the fourth quarter, with an organic growth rate of 3% that exceeded expectations, sets a positive tone for the upcoming fiscal year 2025, despite the challenging conditions of fiscal year 2024.
Repligen’s initial guidance for 9.5%-13.5% organic growth in fiscal year 2025 surpasses the consensus estimate of 9%, indicating the company’s resilience to external pressures such as tariffs and market uncertainties affecting its peers. The launch of innovative products like the AVIPure dsRNA resin and strategic acquisitions further bolster Repligen’s potential for continued success, reinforcing its status as a leader in the bioprocessing industry.